Oneness Biotech Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Oneness Biotech's earnings have been declining at an average annual rate of -25.2%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 36.3% per year.
Wichtige Informationen
-25.2%
Wachstumsrate der Gewinne
-17.6%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 18.5% |
| Wachstumsrate der Einnahmen | 36.3% |
| Eigenkapitalrendite | -7.0% |
| Netto-Marge | -960.4% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Oneness Biotech Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 102 | -979 | 198 | 959 |
| 31 Mar 24 | 90 | -1,141 | 180 | 965 |
| 31 Dec 23 | 87 | -1,313 | 177 | 953 |
| 30 Sep 23 | 76 | -1,469 | 166 | 952 |
| 30 Jun 23 | 71 | -967 | 172 | 979 |
| 31 Mar 23 | 1,068 | -293 | 176 | 940 |
| 31 Dec 22 | 1,066 | 360 | 167 | 919 |
| 30 Sep 22 | 1,069 | 1,131 | 168 | 854 |
| 30 Jun 22 | 1,079 | 679 | 152 | 791 |
| 31 Mar 22 | 75 | -132 | 133 | 739 |
| 31 Dec 21 | 66 | -403 | 117 | 806 |
| 30 Sep 21 | 52 | -1,099 | 105 | 791 |
| 30 Jun 21 | 30 | -901 | 103 | 695 |
| 31 Mar 21 | 49 | 64 | 107 | 727 |
| 31 Dec 20 | 42 | -242 | 108 | 589 |
| 30 Sep 20 | 39 | 156 | 108 | 518 |
| 30 Jun 20 | 42 | 75 | 100 | 481 |
| 31 Mar 20 | 13 | -481 | 80 | 335 |
| 31 Dec 19 | 13 | -322 | 70 | 239 |
| 30 Sep 19 | 16 | -202 | 45 | 170 |
| 30 Jun 19 | 15 | -255 | 40 | 134 |
| 31 Mar 19 | 16 | -209 | 42 | 108 |
| 31 Dec 18 | 19 | -235 | 46 | 94 |
| 30 Sep 18 | 15 | -230 | 70 | 68 |
| 30 Jun 18 | 12 | -151 | 73 | 55 |
| 31 Mar 18 | 10 | -171 | 76 | 58 |
| 31 Dec 17 | 3 | -155 | 75 | 65 |
| 30 Sep 17 | 3 | -149 | 70 | 70 |
| 30 Jun 17 | 4 | -34 | 63 | 70 |
| 31 Mar 17 | 5 | -21 | 58 | 71 |
| 31 Dec 16 | 6 | -14 | 53 | 63 |
| 30 Sep 16 | 6 | -5 | 53 | 57 |
| 30 Jun 16 | 5 | -106 | 48 | 55 |
| 31 Mar 16 | 9 | -103 | 46 | 53 |
| 31 Dec 15 | 8 | -93 | 47 | 54 |
| 30 Sep 15 | 7 | -27 | 54 | 67 |
| 30 Jun 15 | 8 | 172 | 59 | 71 |
| 31 Mar 15 | 5 | 195 | 64 | 60 |
| 31 Dec 14 | 5 | 200 | 60 | 61 |
| 30 Sep 14 | 5 | 118 | 55 | 64 |
| 30 Jun 14 | 4 | 116 | 52 | 61 |
| 31 Mar 14 | 4 | 236 | 46 | 73 |
| 31 Dec 13 | 5 | 276 | 46 | 75 |
Qualität der Erträge: 4743 is currently unprofitable.
Wachsende Gewinnspanne: 4743 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 4743 is unprofitable, and losses have increased over the past 5 years at a rate of 25.2% per year.
Beschleunigtes Wachstum: Unable to compare 4743's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 4743 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 4743 has a negative Return on Equity (-7.03%), as it is currently unprofitable.